Cargando…

Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis

BACKGROUND: Osimertinib resistance limits the treatment of epidermal growth factor receptor-(EGFR)-mutated non-small-cell lung carcinoma (NSCLC). The mechanisms of osimertinib resistance need to be elucidated to determine alternative treatment strategies. This study explores the role of M2 type tumo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wan, Xiaoying, Xie, Boxiong, Sun, Hui, Gu, Weiqing, Wang, Chunyan, Deng, Qinfang, Zhou, Songwen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845243/
https://www.ncbi.nlm.nih.gov/pubmed/35168607
http://dx.doi.org/10.1186/s12935-022-02509-x
_version_ 1784651631011299328
author Wan, Xiaoying
Xie, Boxiong
Sun, Hui
Gu, Weiqing
Wang, Chunyan
Deng, Qinfang
Zhou, Songwen
author_facet Wan, Xiaoying
Xie, Boxiong
Sun, Hui
Gu, Weiqing
Wang, Chunyan
Deng, Qinfang
Zhou, Songwen
author_sort Wan, Xiaoying
collection PubMed
description BACKGROUND: Osimertinib resistance limits the treatment of epidermal growth factor receptor-(EGFR)-mutated non-small-cell lung carcinoma (NSCLC). The mechanisms of osimertinib resistance need to be elucidated to determine alternative treatment strategies. This study explores the role of M2 type tumor-associated macrophage (TAM)-derived exosomal MSTRG.292666.16 in osimertinib resistance, and its related competing endogenous RNA (ceRNA) mechanism. METHODS: M2 type TAMs were induced with 200 ng/mL phorbol 12-myristate 13-acetate, 20 ng/mL IL-4 and IL-13, and M2 type macrophage markers were measured by RT-qPCR. Next, the exosomes were isolated and characterized. Tumor formation in nude mice was conducted using H1975 cells under different treatment conditions. Small RNA sequencing was performed on exosomes derived from sensitive and resistant plasma, and ceRNA networks were constructed. Fluorescence in situ hybridization was used to observe the localization of MSTRG.292666.16, and a ceRNA network (MSTRG.292666.16-miR-6836-5p-MAPK8IP3) was selected for further validation. RESULTS: M2 type TAMs, and M2 type TAM-derived exosomes were successfully induced and isolated. Nude mice results showed that M2 type TAM-derived exosomes and MSTRG.292666.16 overexpression significantly increased tumor volume after administration of osimertinib for 4 weeks. M2 type TAMs were found in the resistant plasma, and MSTRG.292666.16 localized in the cytoplasm of H1975 cells. In addition, the genes in the ceRNA networks were significantly enriched in eight GO terms and seven KEGG pathways, including the MAPK signaling pathway. Subsequently, the levels of MSTRG.292666.16 and MAPK8IP3 significantly increased in both resistant plasma-derived exosomes and M2 type TAM-derived exosomes, while miR-6836-5p levels were significantly reduced. Finally, MSTRG.292666.16, miR-6836-5p, and MAPK8IP3 were part of the same network. CONCLUSIONS: M2 type TAM-derived exosomes promoted osimertinib resistance in NSCLC by regulating the MSTRG.292666.16/miR-6386-5p/MAPK8IP3 axis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02509-x.
format Online
Article
Text
id pubmed-8845243
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88452432022-02-16 Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis Wan, Xiaoying Xie, Boxiong Sun, Hui Gu, Weiqing Wang, Chunyan Deng, Qinfang Zhou, Songwen Cancer Cell Int Primary Research BACKGROUND: Osimertinib resistance limits the treatment of epidermal growth factor receptor-(EGFR)-mutated non-small-cell lung carcinoma (NSCLC). The mechanisms of osimertinib resistance need to be elucidated to determine alternative treatment strategies. This study explores the role of M2 type tumor-associated macrophage (TAM)-derived exosomal MSTRG.292666.16 in osimertinib resistance, and its related competing endogenous RNA (ceRNA) mechanism. METHODS: M2 type TAMs were induced with 200 ng/mL phorbol 12-myristate 13-acetate, 20 ng/mL IL-4 and IL-13, and M2 type macrophage markers were measured by RT-qPCR. Next, the exosomes were isolated and characterized. Tumor formation in nude mice was conducted using H1975 cells under different treatment conditions. Small RNA sequencing was performed on exosomes derived from sensitive and resistant plasma, and ceRNA networks were constructed. Fluorescence in situ hybridization was used to observe the localization of MSTRG.292666.16, and a ceRNA network (MSTRG.292666.16-miR-6836-5p-MAPK8IP3) was selected for further validation. RESULTS: M2 type TAMs, and M2 type TAM-derived exosomes were successfully induced and isolated. Nude mice results showed that M2 type TAM-derived exosomes and MSTRG.292666.16 overexpression significantly increased tumor volume after administration of osimertinib for 4 weeks. M2 type TAMs were found in the resistant plasma, and MSTRG.292666.16 localized in the cytoplasm of H1975 cells. In addition, the genes in the ceRNA networks were significantly enriched in eight GO terms and seven KEGG pathways, including the MAPK signaling pathway. Subsequently, the levels of MSTRG.292666.16 and MAPK8IP3 significantly increased in both resistant plasma-derived exosomes and M2 type TAM-derived exosomes, while miR-6836-5p levels were significantly reduced. Finally, MSTRG.292666.16, miR-6836-5p, and MAPK8IP3 were part of the same network. CONCLUSIONS: M2 type TAM-derived exosomes promoted osimertinib resistance in NSCLC by regulating the MSTRG.292666.16/miR-6386-5p/MAPK8IP3 axis. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-022-02509-x. BioMed Central 2022-02-15 /pmc/articles/PMC8845243/ /pubmed/35168607 http://dx.doi.org/10.1186/s12935-022-02509-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Primary Research
Wan, Xiaoying
Xie, Boxiong
Sun, Hui
Gu, Weiqing
Wang, Chunyan
Deng, Qinfang
Zhou, Songwen
Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis
title Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis
title_full Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis
title_fullStr Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis
title_full_unstemmed Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis
title_short Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis
title_sort exosomes derived from m2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through mstrg.292666.16-mir-6836-5p-mapk8ip3 axis
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8845243/
https://www.ncbi.nlm.nih.gov/pubmed/35168607
http://dx.doi.org/10.1186/s12935-022-02509-x
work_keys_str_mv AT wanxiaoying exosomesderivedfromm2typetumorassociatedmacrophagespromoteosimertinibresistanceinnonsmallcelllungcancerthroughmstrg29266616mir68365pmapk8ip3axis
AT xieboxiong exosomesderivedfromm2typetumorassociatedmacrophagespromoteosimertinibresistanceinnonsmallcelllungcancerthroughmstrg29266616mir68365pmapk8ip3axis
AT sunhui exosomesderivedfromm2typetumorassociatedmacrophagespromoteosimertinibresistanceinnonsmallcelllungcancerthroughmstrg29266616mir68365pmapk8ip3axis
AT guweiqing exosomesderivedfromm2typetumorassociatedmacrophagespromoteosimertinibresistanceinnonsmallcelllungcancerthroughmstrg29266616mir68365pmapk8ip3axis
AT wangchunyan exosomesderivedfromm2typetumorassociatedmacrophagespromoteosimertinibresistanceinnonsmallcelllungcancerthroughmstrg29266616mir68365pmapk8ip3axis
AT dengqinfang exosomesderivedfromm2typetumorassociatedmacrophagespromoteosimertinibresistanceinnonsmallcelllungcancerthroughmstrg29266616mir68365pmapk8ip3axis
AT zhousongwen exosomesderivedfromm2typetumorassociatedmacrophagespromoteosimertinibresistanceinnonsmallcelllungcancerthroughmstrg29266616mir68365pmapk8ip3axis